Finanzen von Phathom Pharmaceuticals Inc (PHAT)PHATPhathom Pharmaceuticals Inc

Evaluating the bottom line, Phathom Pharmaceuticals, Inc. maintains a gross margin of 79.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.34%, while the net margin is -23.67%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PHAT converts its operational activities into shareholder value.

In the context of the broader market, PHAT competes directly with industry leaders such as DBVT and NVCT. With a market capitalization of $774.22M, it holds a significant position in the sector. When comparing efficiency, PHAT's gross margin of 79.68% stands against DBVT's 100.00% and NVCT's N/A. Such benchmarking helps identify whether Phathom Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Phathom reported a total revenue of $74.3 million for Q2 2026, a significant increase of 88% year-over-year, and achieved its first operating profit, indicating improved financial health.